Fundraising Fox

Tr1X Bio

2 known investors

tr1x.bio ↗

Tr1X develops regulatory T cell-based (Tr1) cell therapies that aim to restore immune tolerance and treat autoimmune and inflammatory diseases. Its programs include clinical trials for Crohn's disease, multiple sclerosis, graft versus host disease following stem cell transplant, and autoimmune uveitis.

BiotechHealthtech

Investors · 2

Neva Sgr.Turin
The Column GroupSan Francisco · $30M

In the news

Impact - Tr1X Biotr1x.bio · Feb 2026Tr1X Bio Lands IND Nod, $50M - San Diego Business Journalsdbj.com · Oct 2025Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases - Tr1X Biotr1x.bio · Jan 2024

Frequently asked questions

What does Tr1X Bio do?
Tr1X develops regulatory T cell-based (Tr1) cell therapies that aim to restore immune tolerance and treat autoimmune and inflammatory diseases. Its programs include clinical trials for Crohn's disease, multiple sclerosis, graft versus host disease following stem cell transplant, and autoimmune uveitis.
Who are Tr1X Bio's investors?
Tr1X Bio's investors include Neva Sgr., The Column Group.